InnoCare Pharma Limited
INCPF · OTC
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 625.40M | 482.01M | -770.40M | -886.59M | -0.60 |
| 2023 FY | 738.54M | 610.10M | -651.15M | -631.26M | -0.37 |
| 2024 FY | 1.01B | 871.01M | -525.78M | -440.63M | -0.26 |
| 2025 FY | 2.30B | 2.01B | 440.63M | 625.89M | 0.36 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 10.32B | 2.68B | 8.70B | 1.25B | 7.60B |
| 2023 FY | 9.92B | 2.74B | 8.22B | 1.35B | 7.15B |
| 2024 FY | 9.41B | 2.66B | 6.22B | 1.27B | 6.73B |
| 2025 FY | 10.83B | 2.79B | 7.08B | 1.61B | 7.73B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -565.55M | -370.33M | -935.88M | — | 942.50M |
| 2023 FY | -671.34M | -254.66M | -926.00M | -1.15M | 22.58M |
| 2024 FY | -365.55M | -78.23M | -443.78M | -362.93M | 476.90M |
| 2025 FY | 199.16M | -68.35M | 130.81M | — | 1.10B |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 33.27B | 25.82B | — | — | — |
| 2023 FY | 39.47B | 32.60B | — | — | — |
| 2024 FY | 40.23B | 35.28B | — | — | — |
| 2025 FY | 25.26B | 19.80B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 350.17M | 309.52M | -47.28M | -48.06M | -0.04 |
| 2025 Q3 | 383.63M | 335.20M | -84.00M | -34.00M | -0.02 |
| 2025 Q4 | 1.24B | 1.15B | 656.47M | 696.51M | 0.40 |
| 2026 Q1 | 523.57M | 461.45M | 67.05M | 104.81M | 0.06 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 9.36B | 2.65B | 7.06B | 1.54B | 6.70B |
| 2025 Q3 | 9.52B | 2.84B | 6.82B | 1.67B | 6.66B |
| 2025 Q4 | 10.83B | 2.79B | 7.08B | 1.61B | 7.73B |
| 2026 Q1 | 10.34B | 3.01B | 6.16B | 1.80B | 7.32B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -118.34M | -9.87M | -128.21M | -8.42M | -142.92M |
| 2025 Q3 | -1.00M | -14.00M | -15.00M | — | -117.00M |
| 2025 Q4 | 208.69M | -31.35M | 177.34M | — | 380.24M |
| 2026 Q1 | 15.70M | -19.84M | -4.15M | — | -799.36M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 28.31B | 22.79B | — | — | — |
| 2025 Q3 | 40.91B | 35.76B | — | — | — |
| 2025 Q4 | 25.26B | 19.80B | — | — | — |
| 2026 Q1 | 18.84B | 14.48B | — | — | — |